自發性震顫（ET）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計在預測期內，ET 市場將保持適度成長（複合年成長率 3-5%），這主要得益於診斷率的提高和治療方法的逐步普及。
• 市場仍以學名藥主導，超過 80% 的銷售額來自低成本的口服療法，而且在已建立的藥物類別中，定價權有限。
• BETA受體阻斷劑（主要是Propranolol）仍是主要市場，佔市場佔有率的30%以上，其次是Primidone和其他抗驚厥藥物（總合40%）。
• Gabapentin和美托洛爾保持著穩定的中端市場佔有率，隨著患者數量的增加，預計市場佔有率將逐步成長。
• 雖然在研產品和新療法（例如 urixacartamide）的成長率相對較高（複合年成長率超過 10-12%），但由於基數較低，預計未來幾年市佔率將逐步擴大。
• 肉毒桿菌療法雖然市佔率小規模，但成長迅速（年複合成長率 8-10%），尤其是在難治性疾病患者。
• 整體市場成長受到許多因素的限制，例如學名藥的普及率高、缺乏疾病修正治療以及繼續依賴對症治療作為一線治療。

自發性震顫（ET）概述

自發性震顫（ET）是最常見的慢性神經運動障礙之一，其特徵是動作性震顫和姿勢性震顫，最常涉及手部，較少涉及頭部、聲音或下肢。這種疾病進行性，可顯著損害精細運動技能、日常生活能力和生活品質。

雖然其病理生理機制尚未完全闡明，但普遍認為與小腦功能障礙和運動迴路的異常振盪活動有關。特發性震顫可散發性發生，也可作為遺傳性性疾病出現，且相當一部分患者俱有顯著的遺傳因子。

臨床上，特發性震顫常被誤診或延誤診斷，尤其是在早期階段，因為其症狀與其他運動障礙（如帕金森氏症）的症狀重疊。診斷主要基於臨床觀察，但需輔以神經學檢查和排除繼發性病因。

治療主要以症狀治療為主，第一線藥物包括BETA阻斷劑（例如Propranolol）和抗驚厥藥物（例如Primidone、Gabapentin、托吡酯）。對於難治性或重症病例，可使用肉毒桿菌注射或醫療設備治療（例如腦深部刺激）。新型治療方法則著眼於潛在的神經通路，以改善震顫控制。

主要亮點

• 自發性震顫（ET）患者數量龐大，且呈持續成長趨勢，這主要受人口老化和公眾意識提高的影響。預計在預測期內，其複合年成長率將保持在個位數低點（2-3%）。
• ET 在老年人中更為常見，大多數確診病例集中在 55 歲及以上的患者中，這反映了該疾病與老齡化相關的進展。
• 雖然盛行率很高，但診斷和治療率仍然不足，相當一部分患者要么未接受治療，要么只接受保守治療。
• 目前，治療藥物主要以學名藥為主，具體構成如下：
• BETA阻斷劑佔最大的市佔率（30-35%）。
• 抗癲癇藥物佔病例的 25-30%。
• 剩餘部分分配給輔助性治療。
• 治療模式高度依賴對症治療，很少使用先進或介入性療法。
• 新興治療方法（例如，下一代小分子化合物和神經調節療法）有望逐步改善治療效果，但其短期影響有限。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Praxis Precision Medicines
• Sage Therapeutics
• Jazz Pharmaceuticals
• GE Healthcare
• AbbVie

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前療法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
• 新興療法
  • 重點
  • 值得關注的後期新療法—概述、市場上市預期和KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求以及透過新興療法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Essential Tremor (ET) Market Outlook

Thelansis's "Essential Tremor (ET) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Essential Tremor treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Essential Tremor (ET) Overview

Essential Tremor (ET) is one of the most common chronic neurological movement disorders, characterized by action and postural tremors, most frequently affecting the hands, and less commonly the head, voice, and lower limbs. The disease is progressive in nature and can significantly impair fine motor skills, daily activities, and quality of life.

The pathophysiology is not fully understood but is believed to involve cerebellar dysfunction and abnormal oscillatory activity within motor circuits. ET may occur sporadically or as a familial condition, with a strong genetic component observed in a significant proportion of patients.

Clinically, ET is often underdiagnosed or misdiagnosed, particularly in early stages, due to overlap with other movement disorders such as Parkinson's disease. Diagnosis is primarily clinical, supported by neurological examination and exclusion of secondary causes.

Management is largely symptom-driven, with first-line pharmacological treatments including beta-blockers (e.g., propranolol) and anticonvulsants (e.g., primidone, gabapentin, topiramate). In refractory or severe cases, botulinum toxin injections and device-based interventions (e.g., deep brain stimulation) are utilized. Emerging therapies are targeting underlying neural pathways to improve tremor control.

Key Highlights

• The diagnosed ET population is large and steadily growing, supported by aging demographics and increased awareness, with low-to-mid single digit CAGR (2-3%) over the forecast period.
• ET shows a higher prevalence in older age groups, with the majority of diagnosed cases concentrated in patients aged ≥55 years, reflecting age-related disease progression.
• Despite high prevalence, diagnosis and treatment rates remain suboptimal, with a significant proportion of patients either untreated or managed conservatively.
• The treatment landscape is heavily dominated by generic therapies, with:
• Beta-blockers accounting for the largest share (30-35%)
• Anticonvulsants contributing 25-30%
• Remaining share distributed across adjunct therapies
• Treatment patterns indicate a high reliance on symptomatic control, with limited use of advanced or interventional therapies.
• Emerging therapies (e.g., next-generation small molecules and neuromodulation approaches) are expected to gradually improve treatment outcomes but remain limited in near-term impact.

Market Overview

• The ET market demonstrates moderate growth (3-5% CAGR) over the forecast period, driven by increasing diagnosis rates and gradual therapy uptake.
• The market remains predominantly generic-driven, with: >80% of revenue derived from low-cost oral therapies and Limited pricing power across established drug classes
• Beta-blockers (primarily propranolol) remain the leading segment, contributing 30%+ of total market share, followed by primidone and other anticonvulsants (40% combined).
• Gabapentin and metoprolol contribute a steady mid-tier share, with incremental growth aligned with patient volume expansion.
• Pipeline and novel therapies (e.g., ulixacaltamide) show high relative growth (>10-12% CAGR) but from a low base, gradually increasing their market share toward the later years.
• Botulinum toxin therapies represent a small but growing segment (8-10% CAGR), particularly in refractory patients.
• Overall market growth is constrained by: High generic penetration, Lack of disease-modifying therapies, Continued reliance on first-line symptomatic treatments

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Praxis Precision Medicines
• Sage Therapeutics
• Jazz Pharmaceuticals
• GE Healthcare
• AbbVie

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)